



This letter certifies that [redacted] has registered interest to take part in planned future clinical trials of a recombinant protein vaccine Covid-19 vaccine developed by Vaxine Pty Ltd known as Covax-19 or Spikogen.

This vaccine has been trialled overseas and has already received emergency use authorization by the Iranian FDA, but has not yet received marketing approval in Australia. Notably, we are currently unable to predict if and when our vaccine may be approved by the TGA to allow its sale in Australia.

Vaxine is planning to undertake a series of clinical trials to collect additional data on this vaccine.

If you participate in one of these future vaccine trials, you may be eligible for an exemption if you are subject to an employment mandate.

However, different rules apply to vaccine mandates in each State, so you would need to check with your State Health Department or employer to find out if being a participant in a Covid-19 vaccine trial is an accepted exclusion criterion for the relevant mandate.

Similarly, participation in a future vaccine trial may not qualify people for a vaccine travel exemption, and this again is something you would need to check yourself with relevant authorities.

At this stage we cannot confirm the time of any trial commencement, trial sites or your potential eligibility, but will be back in touch with more information as soon as we can.

Registering your details on this site does not mean you will be enrolled in a future study, but just expresses your interest in being contacted with additional information, if from your data you might be eligible for a particular approved future study.

We respect your privacy and hence will be happy to delete the stored personal details you have provided, upon written request.

Yours sincerely

A handwritten signature in blue ink that reads "Pringle". The signature is written in a cursive, flowing style.

Sharen Pringle  
Clinical Trials Manager